NeOnc Technologies Holdings (NTHI) Q1 2025 earnings summary

Executive summary

• Clinical-stage biopharma focused on novel drug delivery for brain cancers, with lead candidate NEO100 in Phase 2a trials and NEO212 in early clinical development.

• Net loss for Q1 2025 was $38.0M, up from $2.9M in Q1 2024, driven by increased R&D, G&A, share-based compensation, and advisory fees related to Nasdaq listing.

• Raised $11.6M in private placements and listed on Nasdaq in March 2025; cash at quarter-end was $5.4M.

Financial highlights

• Revenue for Q1 2025 was $39,990, from humanitarian use fees, with no product sales.

• Operating expenses rose sharply to $37.6M (from $1.6M), including $23.1M in share-based compensation and $11.7M in advisory fees.

• R&D expenses increased to $998K (from $615K), mainly due to expanded clinical trials and recruitment.

• Cash used in operations was $5.7M; financing activities provided $11.0M, mainly from equity sales.

• Accumulated deficit reached $88.6M as of March 31, 2025.

Outlook and guidance

• Management expects continued significant operating losses as clinical programs advance and public company costs rise.

• Additional funding will be required to support ongoing operations and development; current cash is insufficient for 12 months.

• Potential funding sources include a $10M line of credit and a $50M equity purchase agreement, both undrawn as of quarter-end.